Richard Eric Davis

Richard Eric Davis

Auto-generated profile, based on publicly available information

Richard Eric Davis

Department of Lymphoma-Myeloma, The University of Texas (UT) MD Anderson Cancer Center, Houston, TX, United States

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2016 in Science Signaling
Verified
Journal Article
Closed access
PDF file
JIJo Ishizawa
Jo Ishizawa
KKKensuke Kojima
Kensuke Kojima
DCDhruv Chachad
Dhruv Chachad
PRPeter Ruvolo
Peter Ruvolo
VRVivian Ruvolo
Vivian Ruvolo
MAMichael Andreeff
Michael Andreeff
ONC201 triggers an apoptotic cellular stress response in both solid and blood tumors.

1 September 2016 in Blood
Verified
Journal Article
Closed access
PDF file
SPSujan Piya
Sujan Piya
SKSteven M. Kornblau
Steven M. Kornblau
VRVivian R. Ruvolo
Vivian R. Ruvolo
HMHong Mu
Hong Mu
PRPeter P. Ruvolo
Peter P. Ruvolo
GBGautam Borthakur
Gautam Borthakur
Autophagy is a cellular adaptive mechanism to stress, including that induced by chemotherapeutic agents. Reverse phase protein array suggested that high expression of the essential autophagy-related protein, Atg7, was associated with shorter remission in newly diagnosed acute myeloid leukemia (AML) patient samples, indicating a role in chemoresistance. Knockdown of Atg7 in AML cells using short hairpin RNA markedly increased apoptosis and DNA damage following treatment with cytarabine and idarubicin. Interestingly, coculture of AML cells with stromal cells increased autophagy and chemoresistance in the AML cells exposed to chemotherapeutic agents, and this was reversed following Atg7 knockdown. This effect was further enhanced by concomitant knockdown of Atg7 in both AML and stromal cells. These findings strongly suggest that Atg7, and likely microenvironment autophagy in general, plays an important role in AML chemoresistance. Mechanistic studies revealed that Atg7 knockdown induced a proapoptotic phenotype in AML cells, which was manifested by an increased NOXA expression at the transcriptional level. Finally, in a mouse model of human leukemia, Atg7 knockdown extended overall survival after chemotherapy. Thus, the inhibition of Atg7 appears to be a valid strategy to enhance chemosensitivity, and it could indeed improve outcomes in AML therapy. Publisher9s Note: There is an Inside Blood Commentary on this article in this issue. Key Points Atg7 expression is associated with shorter remission duration in AML. Atg7 inhibition is a proapoptotic phenotype and enhances sensitivity to chemotherapy.

24 August 2017 in Blood
Verified
Journal Article
Closed access
PDF file
OHOndrej Havranek
Ondrej Havranek
JXJingda Xu
Jingda Xu
SKStefan Köhrer
Stefan Köhrer
ZWZhiqiang Wang
Zhiqiang Wang
LBLisa Becker
Lisa Becker
RDR. Eric Davis
R. Eric Davis
Key Points: The GCB subtype of DLBCL relies exclusively on tonic BCR signaling via CD79A Y188. PTEN protein expression and BCR surface density determine the contribution of tonic BCR signaling to AKT activity in GCB-DLBCL.

29 May 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
HLHuan Liu
Huan Liu
JHJin He
Jin He
SKSu Pin Koh
Su Pin Koh
YZYuping Zhong
Yuping Zhong
ZLZhi-Qiang Liu
Zhi-Qiang Liu
JYJing Yang
Jing Yang
Osteolytic lesions in multiple myeloma are caused by osteoclast-mediated bone resorption and reduced bone formation. A unique feature of myeloma is a failure of bone healing after successful treatment. We observed adipocytes on trabecular bone near the resorbed area in successfully treated patients. Normal marrow adipocytes, when cocultured with myeloma cells, were reprogrammed and produced adipokines that activate osteoclastogenesis and suppress osteoblastogenesis. These adipocytes have reduced expression of peroxisome proliferator–activated receptor γ (PPARγ) mediated by recruitment of polycomb repressive complex 2 (PRC2), which modifies PPARγ promoter methylation at trimethyl lysine-27 histone H3. We confirmed the importance of methylation in the PPARγ promoter by demonstrating that adipocyte-specific knockout of EZH2, a member of the PRC2, prevents adipocyte reprogramming and reverses bone changes in a mouse model. We validated the strong correlation between the frequency of bone lesions and the expression of EZH2 in marrow adipocytes from patients in remission. These results define a role for adipocytes in genesis of myeloma-associated bone disease and that reversal of adipocyte reprogramming has therapeutic implications.

19 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
Natalia BaranNatalia Baran
Natalia Baran
ALAlessia Lodi
Alessia Lodi
YDYogesh Dhungana
Yogesh Dhungana
SHShelley Herbrich
Shelley Herbrich
Meghan CollinsMeghan Collins
Meghan Collins
MKMarina Konopleva
Marina Konopleva
T-cell acute lymphoblastic leukemia (T-ALL) is commonly driven by activating mutations in NOTCH1 that facilitate glutamine oxidation. Here we identify oxidative phosphorylation (OxPhos) as a critical pathway for leukemia cell survival and demonstrate a direct relationship between NOTCH1, elevated OxPhos gene expression, and acquired chemoresistance in pre-leukemic and leukemic models. Disrupting OxPhos with IACS-010759, an inhibitor of mitochondrial complex I, causes potent growth inhibition through induction of metabolic shut-down and redox imbalance in NOTCH1-mutated and less so in NOTCH1-wt T-ALL cells. Mechanistically, inhibition of OxPhos induces a metabolic reprogramming into glutaminolysis. We show that pharmacological blockade of OxPhos combined with inducible knock-down of glutaminase, the key glutamine enzyme, confers synthetic lethality in mice harboring NOTCH1-mutated T-ALL. We leverage on this synthetic lethal interaction to demonstrate that IACS-010759 in combination with chemotherapy containing L-asparaginase, an enzyme that uncovers the glutamine dependency of leukemic cells, causes reduced glutaminolysis and profound tumor reduction in pre-clinical models of human T-ALL. In summary, this metabolic dependency of T-ALL on OxPhos provides a rational therapeutic target.

2 April 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
SPSujan Piya
Sujan Piya
HMHong Mu
Hong Mu
SBSeemana Bhattacharya
Seemana Bhattacharya
PLPhilip L Lorenzi
Philip L Lorenzi
RDR. Eric Davis
R. Eric Davis
GBGautam Borthakur
Gautam Borthakur
Anti-leukemic effect of BET/BRD4 (BETP) protein inhibition has been largely attributed to transcriptional downregulation of cellular anabolic/anti-apoptotic processes but its effect on bone marrow microenvironment, a sanctuary favoring persistence of leukemia stem/progenitor cells, is unexplored. Sustained degradation of BETP with small-molecule BET proteolysis-targeting chimera (PROTAC), ARV-825, resulted in marked downregulation of surface CXCR4 and CD44, key proteins in leukemia-microenvironment interaction, in AML cells. Abrogation of surface CXCR4 expression impaired SDF-1α directed migration and was mediated through transcriptional down-regulation of PIM1 kinase that in turn phosphorylates CXCR4 and facilitates its surface localization. Down-regulation of CD44/CD44v8-10 impaired cystine uptake, lowered intracellular reduced glutathione and increased oxidative stress. More importantly, BETP degradation markedly decreased CD34+CD38-CD90-CD45RA+ leukemic stem cell population and alone or in combination with Cytarabine, prolonged survival in mouse model of human leukemia including AML-PDX. Gene expression profiling and single cell proteomics confirmed down regulation of the gene signatures associated with ‘stemness’ in AML and Wnt/β-catenin, Myc pathways. Hence, BETP degradation by ARV-825 simultaneously targets cell intrinsic signaling, stromal interactions and metabolism in AML.